Chester County News and Community Website
PHILADELPHIA, PA — FORE Biotherapeutics announced that its investigational therapy plixorafenib has cleared an interim efficacy analysis in the Phase 2 FORTE basket study for patients with recurrent or progressive …
Fore Bio’s Plixorafenib Clears Interim Review in Brain Tumor Trial Read More PHILADELPHIA, PA — FORE Biotherapeutics announced that it will participate in two upcoming investor conferences next month.
FORE Biotherapeutics to Present at September Investor Conferences Read More PHILADELPHIA, PA — FORE Biotherapeutics, a registration-stage biotherapeutics company, will participate in the Jefferies Global Healthcare Conference on Tuesday, June 3, 2025, in New York.
FORE Biotherapeutics to Present at Jefferies Global Healthcare Conference 2025 Read More PHILADELPHIA, PA — FORE Biotherapeutics recently completed a $38 million Series D-2 financing round, bringing the total raised as part of the Series D to an impressive $113 million. This …
FORE Biotherapeutics Secures $38 Million in Series D-2 Financing Read More PHILADELPHIA, PA — FORE Biotherapeutics has announced that its plixorafenib abstract has been selected for poster presentation at the highly anticipated 2025 American Society of Clinical Oncology Annual Meeting (ASCO), …
FORE Biotherapeutics’ Plixorafenib Study to Be Highlighted at ASCO 2025 Read More PHILADELPHIA, PA — FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. …
FORE Biotherapeutics to Present Plixorafenib Research at AACR Annual Meeting Read More